Search results
Results From The WOW.Com Content Network
And Boehringer Ingelheim is making it available to all Americans, regardless of insurance status," Gemmell said. Cyltezo will sell for $550, a 92% discount from the Humira list price of about $7,000.
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies , and the largest private one.
Boehringer Ingelheim Animal Health is a multinational animal health company, formed in January 2017 when Merial was acquired by Boehringer Ingelheim and merged with Boehringer Ingelheim's existing animal health assets. [3]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
In early 2009 the Boehringer Ingelheim Foundation decided to fund a new centre of excellence in the life sciences.; The federal state of Rhineland-Palatinate financed the construction of a new building, starting in December 2009 on the campus of the University of Mainz.
Boehringer Ingelheim: generalized pustular psoriasis: Futibatinib: Taiho Oncology: intrahepatic cholangiocarcinoma with FGFR2 gene fusions or other rearrangements Teclistamab: Janssen: multiple myeloma: Teplizumab: Provention Bio: delay the onset of stage 3 type 1 diabetes (T1D) in stage 2 T1D Atezolizumab: Genentech: alveolar soft part sarcoma ...
BIBW 2992 is a next-generation tyrosine kinase inhibitor developed by Boehringer Ingelheim which irreversibly blocks both epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase. In the first human study of BIBW 2992, the maximum tolerated dose in a two-week-on, two-week off schedule was 70 mg once-daily. [7]
Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. [30] Of the gliflozins, empagliflozin and tofogliflozin have the highest specificity for SGLT2 inhibition. [1] This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death. [31]